Cargando…

Pharmacokinetic‐pharmacodynamic model of urinary δ‐aminolevulinic acid reduction after givosiran treatment in patients with acute hepatic porphyria

Givosiran, an RNA interference‐based therapeutic, is a recent addition to the limited treatment armamentarium for acute hepatic porphyria (AHP). As a small interfering RNA that is selectively taken up in the liver, both the mechanism and targeted delivery create a complex relationship between givosi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Jongtae, Melch, Megan, Robbie, Gabriel J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272304/ https://www.ncbi.nlm.nih.gov/pubmed/36883675 http://dx.doi.org/10.1002/psp4.12957

Ejemplares similares

Acute intermittent porphyria, givosiran, and homocysteine
por: Fontanellas, Antonio, et al.
Publicado: (2021)

Case Report: Lack of Response to Givosiran in a Case of ALAD Porphyria
por: Graff, Erica, et al.
Publicado: (2022)

PB2559: VARIEGATE PORPHYRIA CONFIRMED BY NGS AND TREATED WITH GIVOSIRAN - CASE PRESENTATION
por: Georgescu, Georgeta Daniela
Publicado: (2023)

Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy
por: Majeed, Chaudry Nasir, et al.
Publicado: (2022)

Normal reference ranges for urinary δ‐aminolevulinic acid and porphobilinogen levels
por: Agarwal, Sagar, et al.
Publicado: (2020)

Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?
por: Petrides, Petro E., et al.
Publicado: (2021)

ALAD Inhibition by Porphobilinogen Rationalizes the Accumulation of δ-Aminolevulinate in Acute Porphyrias
por: San Juan, Itxaso, et al.
Publicado: (2022)

Efficacy and safety of givosiran for acute hepatic porphyria: 24‐month interim analysis of the randomized phase 3 ENVISION study
por: Ventura, Paolo, et al.
Publicado: (2021)

Idiosyncratic drug-induced liver injury caused by givosiran in a patient with acute intermittent porphyria
por: Ma, Christopher D., et al.
Publicado: (2022)

Recurrent symptoms of acute intermittent porphyria after biochemical normalization with givosiran—An ongoing clinical conundrum
por: Ma, Christopher D., et al.
Publicado: (2022)

Evaluating the Efficacy of a Small Interfering Ribonucleic Acid Molecule, Givosiran, in Treating Acute Intermittent Porphyria: A Systematic Review
por: Patel, Priyansh, et al.
Publicado: (2023)

Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib
por: Black, Donald M., et al.
Publicado: (2018)

Assessment of Lead Exposure and Urinary-δ-aminolevulinic Acid Levels in Male Lead Acid Battery Workers in Tamil Nadu, India
por: Kalahasthi, Ravibabu, et al.
Publicado: (2018)

Prenatal Exposure to Lead, δ-Aminolevulinic Acid, and Schizophrenia: Further Evidence
por: Opler, Mark G.A., et al.
Publicado: (2008)

δ-Aminolevulinic Acid Dehydratase Polymorphism and Risk of Brain Tumors in Adults
por: Rajaraman, Preetha, et al.
Publicado: (2005)

δ-Aminolevulinic acid cytotoxic effects on human hepatocarcinoma cell lines
por: De Siervi, Adriana, et al.
Publicado: (2002)

Acute Hepatic Porphyria
por: Bissell, D. Montgomery, et al.
Publicado: (2015)

Reassessment of the threshold of the blood lead level to increase urinary δ‐aminolevulinic acid based on their relationship in recent lead workers in Japan
por: Ono, Akira, et al.
Publicado: (2021)

Effects of δ‐aminolevulinic acid dehydratase silencing on the primary and secondary metabolisms of citrus
por: Killiny, Nabil, et al.
Publicado: (2018)

Derivative Matrix-Isopotential Synchronous Spectrofluorimetry and Hantzsch Reaction: A Direct Route to Simultaneous Determination of Urinary δ-Aminolevulinic Acid and Porphobilinogen
por: Ajmal, Muhammad, et al.
Publicado: (2022)

δ-Aminolevulinic acid transport in murine mammary adenocarcinoma cells is mediated by beta transporters
por: Bermúdez Moretti, M, et al.
Publicado: (2002)

Role of δ-Aminolevulinic Acid Dehydratase (ALAD) gene polymorphism in lead induced nephrotoxicity
por: Tiwari, Mugdha, et al.
Publicado: (2014)

Saturable human neopterin response to interferon-α assessed by a pharmacokinetic-pharmacodynamic model
por: Jeon, Sangil, et al.
Publicado: (2013)

STUDIES IN PORPHYRIA : II. EVIDENCE FOR A DEFICIENCY OF STEROID Δ(4)-5α-REDUCTASE ACTIVITY IN ACUTE INTERMITTENT PORPHYRIA
por: Bradlow, H. Leon, et al.
Publicado: (1973)

Effect of ursodeoxycholic acid on experimental hepatic porphyria induced by griseofulvin.
por: Choi, S. W., et al.
Publicado: (1991)

Mechanistic studies on δ-aminolevulinic acid uptake and efflux in a mammary adenocarcinoma cell line
por: Correa García, S, et al.
Publicado: (2003)

Lead and δ-Aminolevulinic Acid Dehydratase Polymorphism: Where Does It Lead? A Meta-Analysis
por: Scinicariello, Franco, et al.
Publicado: (2007)

Acute hepatic porphyria and hepatocellular carcinoma.
por: Kauppinen, R., et al.
Publicado: (1988)

Endothelial Dysfunction in Acute Hepatic Porphyrias
por: Ricci, Andrea, et al.
Publicado: (2022)

Metabolic engineering of microorganisms for the production of multifunctional non‐protein amino acids: γ‐aminobutyric acid and δ‐aminolevulinic acid
por: Su, Anping, et al.
Publicado: (2021)

Acute Hepatic Porphyrias: Review and Recent Progress
por: Wang, Bruce, et al.
Publicado: (2018)

Mechanisms of Neuronal Damage in Acute Hepatic Porphyrias
por: Ricci, Andrea, et al.
Publicado: (2021)

Pathogenesis of acute encephalopathy in acute hepatic porphyria
por: Pischik, Elena, et al.
Publicado: (2023)

THE PORPHYRIAS
Publicado: (1981)

Liver δ-Aminolevulinate Dehydratase Activity is Inhibited by Neonicotinoids and Restored by Antioxidant Agents
por: Sauer, Elisa, et al.
Publicado: (2014)

Influence of gestational diabetes on the activity of δ-aminolevulinate dehydratase and oxidative stress biomarkers
por: Rodrigues, Fabiane, et al.
Publicado: (2017)

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
por: Frost, Charles E., et al.
Publicado: (2021)

Use of Generalized Additive Model to Detect the Threshold of δ-Aminolevulinic Acid Dehydratase Activity Reduced by Lead Exposure
por: Huang, Chan-Ching, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7qao5ptki9a0n9a1jo0gpd10t3